Rennie Andrew T, DeWeerd Alexander J, Martinez Maria G, Kay Christine N
Clinical Sciences, Florida State University College of Medicine, Tallahassee, USA.
Clinical Sciences, Vitreo Retinal Associates, Gainesville, USA.
Cureus. 2022 Jul 31;14(7):e27502. doi: 10.7759/cureus.27502. eCollection 2022 Jul.
A 21-year-old female developed bilateral acute-onset paracentral scotomas three days after receiving the second dose of her Moderna COVID-19 vaccination. A clinical diagnosis of acute macular neuroretinopathy (AMN) was confirmed after classic findings were demonstrated on near-infrared reflectance imaging, spectral-domain optical coherence tomography, and colored fundus photography. The patient presented with visual acuity of 20/100-1 OD and 20/20 OS. After treatment with brimonidine and difluprednate, at a two-week follow-up, her visual acuity was 20/100-2 OD and 20/25-2 OS. There have been reported cases of AMN following flu-like illnesses as well as after receiving vaccines. However, this is the first report of AMN following vaccination with a Moderna COVID-19 vaccine.
一名21岁女性在接种第二剂莫德纳新冠疫苗三天后出现双侧急性发作的旁中心暗点。在近红外反射成像、光谱域光学相干断层扫描和彩色眼底摄影显示出典型表现后,急性黄斑神经视网膜病变(AMN)的临床诊断得到证实。患者右眼视力为20/100,左眼视力为20/20。在用溴莫尼定和地氟泼尼龙治疗后,两周随访时,她的右眼视力为20/100,左眼视力为20/25。此前有流感样疾病后以及接种疫苗后出现AMN的病例报告。然而,这是首例接种莫德纳新冠疫苗后出现AMN的报告。